Insider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells 4,148 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson sold 4,148 shares of the company’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total value of $149,991.68. Following the sale, the chief financial officer now owns 102,464 shares in the company, valued at approximately $3,705,098.24. This trade represents a 3.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

BridgeBio Pharma Price Performance

Shares of BBIO opened at $36.81 on Friday. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $39.47. The stock has a market cap of $6.96 billion, a PE ratio of -15.27 and a beta of 1.07. The firm has a fifty day moving average price of $31.71 and a 200 day moving average price of $27.85.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.22). As a group, equities analysts expect that BridgeBio Pharma, Inc. will post -2.56 EPS for the current fiscal year.

Hedge Funds Weigh In On BridgeBio Pharma

A number of hedge funds have recently modified their holdings of the business. Mackenzie Financial Corp raised its position in BridgeBio Pharma by 6.6% in the 4th quarter. Mackenzie Financial Corp now owns 9,505 shares of the company’s stock valued at $261,000 after purchasing an additional 592 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in BridgeBio Pharma in the fourth quarter valued at $109,000. Frazier Life Sciences Management L.P. raised its holdings in shares of BridgeBio Pharma by 1.1% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock valued at $104,285,000 after buying an additional 40,000 shares during the last quarter. Woodline Partners LP boosted its stake in shares of BridgeBio Pharma by 132.9% during the fourth quarter. Woodline Partners LP now owns 2,211,521 shares of the company’s stock worth $60,684,000 after buying an additional 1,261,772 shares during the period. Finally, Zimmer Partners LP acquired a new stake in shares of BridgeBio Pharma during the fourth quarter worth about $4,950,000. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on BBIO shares. HC Wainwright restated a “buy” rating and set a $49.00 target price on shares of BridgeBio Pharma in a research note on Thursday, February 13th. Evercore ISI boosted their price target on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a report on Monday, December 23rd. Scotiabank raised their price objective on shares of BridgeBio Pharma from $48.00 to $49.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 12th. Finally, Bank of America boosted their target price on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, BridgeBio Pharma has an average rating of “Moderate Buy” and a consensus price target of $49.08.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.